B+
Bull case
25%
Probability
Target price
$2.00
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
STXS
StereotaxisCNYSE American / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.40
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.65
Analysis reference price unavailable
Analysis 2026-09-30 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-30
Recent news sentiment (30D)
-26.0
Negative
Company
-
Unavailable
Macro
-26.0
Negative
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+91.5
Score
AI commentary
Primary-source operating news is encouraging but early-stage. The packet provides no reliable post-release price reaction, analyst revisions, social-coverage measure, options skew, short-interest figure or employee score; the zero sentiment fields denote unavailable data, not neutral measurements. Low coverage and a loose peer set warrant monitoring rather than a high-conviction call.
RankAlpha Sentiment Codex - 2026-09-30
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-20eventFirst U.S. GenesisX installationHigh impact
The company reported its first U.S. hospital purchase of a GenesisX robotic system and said installation was planned for fall 2026. Completion and subsequent utilization would provide a more concrete adoption signal; the installation date and procedure volumes remain unconfirmed [#SEC-8K-2026-08-11].
2026-12-31catalystMAGiC manufacturing and recurring-revenue rampHigh impact
Q2 robotic-catheter revenue exceeded $1 million, while management attributed procedural pressure partly to limited catheter supply. It forecast recurring revenue of approximately $7 million in Q3 and $8 million in Q4, contingent on increasing MAGiC manufacturing. Achievement, rather than the forecast alone, would strengthen the commercialization case [#8-K-2026-08-11] [#SEC-8K-2026-08-11].
2027-06-30catalystCash-flow profitability objectiveHigh impact
Management anticipates cash-flow profitability in the first half of 2027 while integrating Robocath. Q2 free cash flow was negative $3.7 million against $10.5 million of June 30 cash, making revenue conversion and spending discipline critical [#SEC-8K-2026-08-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-30 • Updated nightlySource: Internal modelMethodology